News
-
-
COMMUNIQUÉ DE PRESSE
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
NanoViricides, Inc. announces advancing lead candidate NV-387 into Phase II clinical development for MPox. Protocol development and site addition underway in the DRC. Focus on antiviral drug against MPox/Smallpox -
-
-
COMMUNIQUÉ DE PRESSE
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
NanoViricides, Inc. announces the effectiveness of broad-spectrum antiviral drug NV-387 against COVID variants and Bird Flu, positioning it well for pandemic preparedness -
-
-
-
-
